209 related articles for article (PubMed ID: 37815820)
1. Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
Singh H; Kang A; Bloudek L; Hsu LI; Corinna Palanca-Wessels M; Stecher M; Siadak M; Ng K
JNCI Cancer Spectr; 2024 Jan; 8(1):. PubMed ID: 37815820
[TBL] [Abstract][Full Text] [Related]
2. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
[TBL] [Abstract][Full Text] [Related]
3. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
[TBL] [Abstract][Full Text] [Related]
4. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
6. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
[TBL] [Abstract][Full Text] [Related]
7. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
[TBL] [Abstract][Full Text] [Related]
8. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.
Chen N; He L; Zou Q; Deng H
Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
[TBL] [Abstract][Full Text] [Related]
9. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
Sandhu J; Wang C; Fakih M
J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
[TBL] [Abstract][Full Text] [Related]
10. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
11. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
Bekaii-Saab TS; Lach K; Hsu LI; Siadak M; Stecher M; Ward J; Beckerman R; Strickler JH
Oncologist; 2023 Oct; 28(10):885-893. PubMed ID: 37463037
[TBL] [Abstract][Full Text] [Related]
12. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
[TBL] [Abstract][Full Text] [Related]
13. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
Richman SD; Southward K; Chambers P; Cross D; Barrett J; Hemmings G; Taylor M; Wood H; Hutchins G; Foster JM; Oumie A; Spink KG; Brown SR; Jones M; Kerr D; Handley K; Gray R; Seymour M; Quirke P
J Pathol; 2016 Mar; 238(4):562-70. PubMed ID: 26690310
[TBL] [Abstract][Full Text] [Related]
14. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
De Cuyper A; Van Den Eynde M; Machiels JP
Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
[TBL] [Abstract][Full Text] [Related]
15. HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer.
Huang W; Chen Y; Chang W; Ren L; Tang W; Zheng P; Wu Q; Liu T; Liu Y; Wei Y; Xu J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):993-1002. PubMed ID: 34156520
[TBL] [Abstract][Full Text] [Related]
16. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
[TBL] [Abstract][Full Text] [Related]
17. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
Itkin B; Garcia A; Straminsky S; Adelchanow ED; Pereyra M; Haab GA; Bardach A
PLoS One; 2021; 16(9):e0257976. PubMed ID: 34591928
[TBL] [Abstract][Full Text] [Related]
19. HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients.
Abdul Razzaq EA; Venkatachalam T; Bajbouj K; Rahmani M; Mahdami A; Rawat S; Mansuri N; Alhashemi H; Hamoudi RA; Bendardaf R
Libyan J Med; 2021 Dec; 16(1):1955462. PubMed ID: 34319852
[No Abstract] [Full Text] [Related]
20. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients.
Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H
Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
